128212 20241125101201.0 doi 10.1038/s41467-023-41768-8 sideral 135427 ART-2023-135427 eng Moreo, Eduardo Universidad de Zaragoza (orcid)0000-0002-0182-201X Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung 2023 Access copy available to the general public Unrestricted Intravesical administration of Bacillus Calmette-Guérin (BCG) was one of the first FDA-approved immunotherapies and remains a standard treatment for bladder cancer. Previous studies have demonstrated that intravenous (IV) administration of BCG is well-tolerated and effective in preventing tuberculosis infection in animals. Here, we examine IV BCG in several preclinical lung tumor models. Our findings demonstrate that BCG inoculation reduced tumor growth and prolonged mouse survival in models of lung melanoma metastasis and orthotopic lung adenocarcinoma. Moreover, IV BCG treatment was well-tolerated with no apparent signs of acute toxicity. Mechanistically, IV BCG induced tumor-specific CD8+ T cell responses, which were dependent on type 1 conventional dendritic cells, as well as NK cell-mediated immunity. Lastly, we also show that IV BCG has an additive effect on anti-PD-L1 checkpoint inhibitor treatment in mouse lung tumors that are otherwise resistant to anti-PD-L1 as monotherapy. Overall, our study demonstrates the potential of systemic IV BCG administration in the treatment of lung tumors, highlighting its ability to enhance immune responses and augment immune checkpoint blockade efficacy. info:eu-repo/grantAgreement/ES/DGA/LMP50-21 info:eu-repo/grantAgreement/EC/H2020/725091/EU/Functional characterisation of mitochondrial metabolic adaptations to innate sensing in dendritic cell subsets/MITOMAD This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 725091-MITOMAD info:eu-repo/grantAgreement/ES/ISCIII/CB21-13-100087 info:eu-repo/grantAgreement/ES/ISCIII/CP20-00106 info:eu-repo/grantAgreement/EUR/MCIN/AEI/CPP2021-008310 info:eu-repo/grantAgreement/ES/MCINN/PID2021-123795OB-I00 info:eu-repo/grantAgreement/ES/MICINN/PID2019-108157RB info:eu-repo/grantAgreement/ES/MICINN/RTI2018-097625-B-100 info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 14.7 2023 MULTIDISCIPLINARY SCIENCES 8 / 134 = 0.06 2023 Q1 T1 4.887 2023 Biochemistry, Genetics and Molecular Biology (miscellaneous) 2023 Q1 Physics and Astronomy (miscellaneous) 2023 Q1 Chemistry (miscellaneous) 2023 Q1 24.9 2023 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Jarit-Cabanillas, Aitor Robles-Vera, Iñaki Uranga, Santiago Universidad de Zaragoza (orcid)0000-0001-7866-2803 Guerrero, Claudia Universidad de Zaragoza (orcid)0000-0002-7963-7797 Gómez, Ana Belén Universidad de Zaragoza (orcid)0000-0002-9713-2127 Mata-Martínez, Pablo Minute, Luna Araujo-Voces, Miguel Felgueres, María José Esteso, Gloria Uranga-Murillo, Iratxe Arias, Maykel Pardo, Julián Universidad de Zaragoza (orcid)0000-0003-0154-0730 Martín, Carlos Universidad de Zaragoza (orcid)0000-0003-2993-5478 Valés-Gómez, Mar del Fresno, Carlos Sancho, David Aguiló, Nacho Universidad de Zaragoza (orcid)0000-0001-7897-9173 1011 630 Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Área Microbiología 1011 566 Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Área Inmunología 1011 X Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Proy. investigación HQA 14, 1 (2023), 690[ 17 pp] Nature communications 2041-1723 5108133 http://zaguan.unizar.es/record/128212/files/texto_completo.pdf Versión publicada 2399273 http://zaguan.unizar.es/record/128212/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:128212 articulos driver 2024-11-22-12:11:42 ARTICLE